Friulchem
On 23 July 2019, Friulchem S.p.A. obtained admission to negotiate ordinary shares on AIM Italia, a multilateral negotiations system organized and managed by Borsa Italiana. Negotiations began on 25 July 2019.
Integrae SIM acted as Nomad, Global Coordinator, Private Placement Bookrunner, and Specialist of the Issuer.
The total equivalent of the resources raised through the operation amounts to Euro 4.5 million, through the issuance of 2,499,750 newly issued shares without nominal value.
The placement price The unit price of the shares resulting from the placement was set at Euro 1.80; based on this price, the market capitalization at the beginning of the negotiations was equal to Euro 14.4 million.
The enterprise. Friulchem (AIM: FCM), active for over 20 years on the market, is today one of the main Italian CDMOs (Contract Development Manufacturing Organizations) active internationally in healthcare through the research and development and production on behalf of third parties of semi-finished and finished products containing both pharmaceutical active ingredients and food supplements, with particular specialization in so-called drug delivery systems for the veterinary sector that represents Friulchem’s excellence, and in the development of dossiers for generic drugs for the human sector. Friulchem is an innovative SME and B2B company with an appreciable propensity for the end client to have solid Italian roots thanks to the production plant in Vivaro (Pordenone) and the administrative headquarters in Milan. The Company, strongly oriented to R&D, boasts consolidated relationships with the main multinationals in the pharmaceutical sector.
Ultima Ricerca Friulchem
UPDATE| In 1H26A, RT&L recorded a Value of Production of € 6.24 mn and revenues of € 6.15 mn, with Customs Brokerage confirming its role as the Group’s main business pillar. EBITDA amounted to € 1.00 mn, with an EBITDA margin of 16.1%, affected by Olitrans’ start-up costs and higher post-listing structural costs. After € 0.46 mn of depreciation, amortization and provisions, mainly related to the amortization of P&A Spedizioni’s goodwill, EBIT stood at € 0.54 mn, with an EBIT margin of 8.6%, while Net Income amounted to € 0.35 mn. NFP further improved, remaining cash positive at € 5.59 mn compared to € 5.30 mn at year-end 2025, mainly supported by cash generation from Customs Brokerage, despite the temporary working capital absorption related to the launch of Olitrans. Following the end of the period, on September 10, 2026, RT&L completed the reverse take-over of the LandS Group, acquiring 100% of its share capital: a transformational transaction that significantly expands the Group’s scale and geographical coverage, strengthens the weight of Customs Brokerage and makes cash generation more recurring and predictable. In light of the results published in the half-year financial report as of June 30, 2026, and the completion of the acquisition of LandS, we are revising our estimates for the coming years. Specifically, we estimate FY26E production value at €18.00 million and EBITDA at €3.20 million, corresponding to a margin of 17.8%. For subsequent years, we expect production value to increase to €32.00 million (CAGR 25A–28E: 44.4%) in FY28E, with EBITDA of €5.60 million (corresponding to a margin of 17.3% of production value), up from €2.69 million in FY25A (corresponding to an EBITDA margin of 25.3%). On the balance sheet, we estimate a cash-positive NFP of €6.70 million for FY28E. We conducted the valuation of RT&L’s equity value using the DCF method and multiples from a sample of comparable companies. The DCF method (which, for prudential purposes, also includes a specific risk of 2.5% in the WACC calculation) yields an equity value of €66.9 million. RT&L’s equity value, calculated using market multiples, comes to €34.2 million. This results in an average equity value of approximately €50.6 million. The target price is €4.30, with a BUY rating and MEDIUM risk. |
